BOT - Anything but charting, page-4946

Very enlightening background look at Brickell Biotech SB and it’s connections below.

So will BOT keep Brickell Biotech’s trademarked name “Sahareo”

Competitor: glycoporonium Bromide seems to cause more skin irritation and rashes than SB.

We know that on Cardigan results SB was bought out by us. We know that the CEO of Brickell was the former CMO of Eli Lilly. In 2022 Eli Lily divested from its position in Qbrexa after buying the drug from Dumira for $1.3 Billion. Did they see SB becoming a major threat to Qbrexa sales?

I have always thought the Pfizer tie of all the management of BOT meant that they would be the most likely BP buyout contender. However perhaps Eli Lily has a open spot now and is looking for a better drug / gel not a wipe with improved side-effects?

I am impressed that BOT managed to interject itself as swoop up the drug. Getting this through FDA approval will make it an appealing target.

Really great background research can be seen below.